Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Granutec

This article was originally published in The Tan Sheet

Executive Summary

Granutec: Agrees to stop using Tylenol gelcap red-and-yellow color scheme for private-label products in a settlement with McNeil. Under the agreement, "in lieu of a recall, Granutec will change the colors of its encapsulated generic acetaminophen, as well as its generic versions of the Tylenol PM and Mylanta gelcaps," McNeil announced on April 19. Granutec also will be prohibited from imitating the colors of "all current and future multi-colored OTC gelatin products" sold by J&J subsidiaries. The generics company will pay McNeil $250,000 for legal fees. McNeil won a preliminary injunction against the Novopharm subsidiary in December. The order, and a later modifying provision, instructed Granutec to initiate a customer recall for all products resembling Tylenol gelcaps ("The Tan Sheet" Jan. 15, p. 3)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel